David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2676
Mizuho Financial
MFG
$127B
| $813K | ﹤0.01% |
265,774
-182,403
| -41% | -$571K |
|
2677
CALL
Warner Bros
WBD
$72.1B
| $811K | ﹤0.01% |
30,000
-38,800
| -56% | -$1.08M |
|
2678
Scansource
SCSC
$1.14B
| $810K | ﹤0.01% |
+22,600
| New | +$845K |
|
2679
TransAlta
TAC
$4B
| $810K | ﹤0.01% |
110,200
-19,100
| -15% | -$109K |
|
2680
Atlanta Braves Holdings Series B
BATRK
$3.31B
| $809K | ﹤0.01% |
29,126
-6,135
| -17% | -$169K |
|
2681
TransDigm Group
TDG
$66.7B
| $809K | ﹤0.01% |
1,782
+782
| +78% | +$317K |
|
|
BMTC
2682
DELISTED
Bryn Mawr Bank Corp
BMTC
| $807K | ﹤0.01% |
22,349
-14,985
| -40% | -$568K |
|
2683
Domino's
DPZ
$11.4B
| $805K | ﹤0.01% |
3,119
-4,269
| -58% | -$1.11M |
|
|
AL
2684
PUT
DELISTED
Air Lease Corp
AL
| $804K | ﹤0.01% |
23,400
+12,300
| +111% | +$444K |
|
2685
Exelixis
EXEL
$13.9B
| $804K | ﹤0.01% |
33,794
-83,184
| -71% | -$1.9M |
|
|
ENZ
2686
DELISTED
Enzo Biochem, Inc.
ENZ
| $802K | ﹤0.01% |
293,953
+55,588
| +23% | +$182K |
|
|
FBM
2687
DELISTED
Foundation Building Materials, Inc. Common Stock
FBM
| $795K | ﹤0.01% |
80,840
+15,698
| +24% | +$152K |
|
2688
TriplePoint Venture Growth BDC
TPVG
$217M
| $794K | ﹤0.01% |
+57,736
| New | +$736K |
|
|
GBT
2689
PUT
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $794K | ﹤0.01% |
15,000
| – | – |
|
|
CZZ
2690
DELISTED
Cosan Limited
CZZ
| $794K | ﹤0.01% |
68,475
-25,901
| -27% | -$285K |
|
2691
Silicom
SILC
$258M
| $791K | ﹤0.01% |
20,676
+11,088
| +116% | +$402K |
|
2692
Theravance Biopharma
TBPH
$884M
| $791K | ﹤0.01% |
34,871
-40,163
| -54% | -$1.02M |
|
|
LDL
2693
PUT
DELISTED
Lydall, Inc.
LDL
| $791K | ﹤0.01% |
33,700
| – | – |
|
|
MSGN
2694
DELISTED
MSG Networks Inc.
MSGN
| $791K | ﹤0.01% |
36,353
+2,565
| +8% | +$59.1K |
|
2695
FTI Consulting
FCN
$4.19B
| $784K | ﹤0.01% |
10,206
-11,316
| -53% | -$799K |
|
2696
Dave & Buster's
PLAY
$343M
| $783K | ﹤0.01% |
+15,708
| New | +$771K |
|
|
UNIT
2697
PUT
Uniti Group
UNIT
$2.47B
| $783K | ﹤0.01% |
70,000
-8,000
| -10% | -$117K |
|
|
ZEUS
2698
DELISTED
Olympic Steel
ZEUS
| $783K | ﹤0.01% |
49,314
-14,823
| -23% | -$266K |
|
2699
CALL
Ashland
ASH
$3.4B
| $781K | ﹤0.01% |
10,000
| – | – |
|
|
QADA
2700
DELISTED
QAD Inc.
QADA
| $780K | ﹤0.01% |
18,112
-16,364
| -47% | -$702K |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.